Clinical Trials Browser

pasireotide × Endocrine × Clear all

NCT06784752 2026-04-30

NETTER-3

Phase 3 Recruiting

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT06295952 2026-03-04

A Study of Pasireotide in People With Prolactinoma

Phase 2 Recruiting

Prolactin-Producing Pituitary Tumor

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase 2 Completed

29 enrolled 11 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

Phase 4 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Phase 2 Withdrawn

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Phase 1 Completed

Acromegaly, Carcinoid Tumor

NCT01364415 2020-12-21

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Phase 1 Completed

Neuroendocrine Tumors

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Phase 3 Completed

123 enrolled 27 charts

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01590199 2019-04-16

MACS2002

Phase 1 Completed

Neuroendocrine Tumors

NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Phase 1 Completed

EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

NCT01137682 2018-04-05

PAOLA

Phase 3 Completed

198 enrolled 17 charts

Acromegaly, Pituitary Neoplasms

NCT00929669 2017-11-28

LAR

Phase 2 Terminated

2 enrolled 3 charts

Pituitary Neoplasms

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1 Completed

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT00690430 2013-07-30

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Phase 3 Completed

186 enrolled 11 charts

Carcinoid Tumor

NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Phase 2 Completed

45 enrolled 10 charts

Carcinoid Tumor, Serotonin Syndrome